Brumfitt W, Hamilton-Miller J M
Urinary Infection Clinic, Royal Free Hospital, London, UK.
Infection. 1995 Mar-Apr;23(2):98-102. doi: 10.1007/BF01833874.
One hundred and twenty women, aged between 18 and 90 years, with a history of at least four episodes of symptomatic urinary tract infection in the preceding 12 months, were randomized in an open, prospective study to prophylactic treatment with cefaclor 250 mg at bedtime or macrocrystalline nitrofurantoin 50 mg at bedtime for 12 months. Ninety-seven (49 taking cefaclor, 48 taking macrocrystalline nitrofurantoin) were assessed for efficacy; 80% of these were symptomatically improved and remained abacteriuric during the period of prophylaxis. Symptomatic attacks while patients were taking prophylaxis occurred at least five times less often than before prophylaxis had started. Seventy percent of the patients continued in an improved condition after having stopped prophylaxis. All 120 patients were assessed for adverse events; these were twice as frequent in patients taking macrocrystalline nitrofurantoin (20% vs. 10%), but only 11 patients (three taking cefaclor, eight taking macrocrystalline nitrofurantoin) withdrew from the study. Due to the small numbers of patients experiencing adverse events, these differences are not statistically significant. No significant changes in haematological or biochemical parameters were found during or after the end of the 12-month course. The 22 patients assessable for efficacy who had a non-obstructive radiological abnormality responded as well to prophylaxis as those with no detectable abnormality. Long-term, low-dose prophylaxis with a suitable antimicrobial agent is highly effective management for patients with recurrent urinary tract infections, and can appropriately be provided by the family doctor. Prophylaxis given for 1 year gives better results than when given for 6 months.
120名年龄在18至90岁之间、在过去12个月中有至少4次症状性尿路感染病史的女性,被纳入一项开放性前瞻性研究,随机分为两组,一组在睡前服用250毫克头孢克洛进行预防性治疗,另一组在睡前服用50毫克大结晶型呋喃妥因,疗程为12个月。对97名患者(49名服用头孢克洛,48名服用大结晶型呋喃妥因)进行了疗效评估;其中80%的患者症状得到改善,且在预防期间保持无细菌尿。患者在接受预防治疗期间出现症状性发作的频率至少比开始预防治疗前低五倍。70%的患者在停止预防治疗后病情仍持续改善。对所有120名患者进行了不良事件评估;服用大结晶型呋喃妥因的患者不良事件发生率是服用头孢克洛患者的两倍(20%对10%),但只有11名患者(3名服用头孢克洛,8名服用大结晶型呋喃妥因)退出了研究。由于经历不良事件的患者数量较少,这些差异无统计学意义。在12个月疗程期间及结束后,未发现血液学或生化参数有显著变化。22名可评估疗效且有非梗阻性放射学异常的患者对预防治疗的反应与无明显异常的患者相同。对于复发性尿路感染患者,使用合适的抗菌药物进行长期低剂量预防是非常有效的治疗方法,家庭医生可适当提供这种治疗。预防治疗1年比预防治疗6个月效果更好。